Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Edwards

Showing results (181-190 of 196) with videos related to

Pageof 20
Sort By:
Advances in Therapy|December 16, 2024
Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised IndividualsChristoph D Spinner, Samira Bell, Hermann Einsele, et al.
Annals of the Rheumatic Diseases|May 15, 2023
Points to consider: EULAR-UEMS standards for the training of European rheumatologistsAlessia Alunno, Tadej Avcin, Catherine Haines, et al.
Annals of Internal Medicine|July 29, 2024
Pain Reduction With Oral Methotrexate in Knee Osteoarthritis : A Randomized, Placebo-Controlled Clinical TrialSarah R Kingsbury, Puvan Tharmanathan, Ada Keding, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 16, 2017
Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's SyndromeSimon J Bowman, Colin C Everett, John L O'Dwyer, et al.
The Journal of Rheumatology. Supplement|March 3, 2011
Algorithm for identification of undifferentiated peripheral inflammatory arthritis: a multinational collaboration through the 3e initiativeGlen Hazlewood, Daniel Aletaha, Loreto Carmona, et al.
Lancet (London, England)|January 24, 2021
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Patrick Durez, Maya H Buch, et al.
The Journal of Antimicrobial Chemotherapy|June 16, 2026
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infectionSaye H Khoo, Richard FitzGerald, Christopher J Edwards, et al.
The Lancet. Infectious Diseases|October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trialSaye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
Nature Communications|November 26, 2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trialI'ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, et al.
Annals of the Rheumatic Diseases|July 23, 2013
Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiativeFrancisca Sivera, Mariano Andrés, Loreto Carmona, et al.
Pageof 20

Showing results (181-190 of 196) with videos related to

Sort By:
Pageof 20
Advances in Therapy|December 16, 2024
Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised IndividualsChristoph D Spinner, Samira Bell, Hermann Einsele, et al.
Annals of the Rheumatic Diseases|May 15, 2023
Points to consider: EULAR-UEMS standards for the training of European rheumatologistsAlessia Alunno, Tadej Avcin, Catherine Haines, et al.
Annals of Internal Medicine|July 29, 2024
Pain Reduction With Oral Methotrexate in Knee Osteoarthritis : A Randomized, Placebo-Controlled Clinical TrialSarah R Kingsbury, Puvan Tharmanathan, Ada Keding, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 16, 2017
Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's SyndromeSimon J Bowman, Colin C Everett, John L O'Dwyer, et al.
The Journal of Rheumatology. Supplement|March 3, 2011
Algorithm for identification of undifferentiated peripheral inflammatory arthritis: a multinational collaboration through the 3e initiativeGlen Hazlewood, Daniel Aletaha, Loreto Carmona, et al.
Lancet (London, England)|January 24, 2021
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Patrick Durez, Maya H Buch, et al.
The Journal of Antimicrobial Chemotherapy|June 16, 2026
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infectionSaye H Khoo, Richard FitzGerald, Christopher J Edwards, et al.
The Lancet. Infectious Diseases|October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trialSaye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
Nature Communications|November 26, 2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trialI'ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, et al.
Annals of the Rheumatic Diseases|July 23, 2013
Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiativeFrancisca Sivera, Mariano Andrés, Loreto Carmona, et al.
Pageof 20